Clinical Trial

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Study acronym: POETYK-PsO-Ped
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis
Protocol Amendment History 4 changes
notable Trial sites expanded: 129 -> 132 locations 2026-08-12
notable Trial sites expanded: 123 -> 127 locations 2026-06-19
notable Trial sites expanded: 120 -> 123 locations 2026-05-29
notable Trial sites expanded: 116 -> 120 locations 2026-05-01
Trial Details
NCT Number NCT06979453
Lead Sponsor Bristol-Myers Squibb
Conditions Plaque Psoriasis
Enrollment 366 participants
Start Date 2025-12-03
Primary Completion 2029-10-12 (estimated)
Study Completion 2034-08-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-11